UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of idiopathic nephrotic syndrome in children

Author
Patrick Niaudet, MD
Section Editor
Tej K Mattoo, MD, DCH, FRCP
Deputy Editor
Melanie S Kim, MD

INTRODUCTION

The nephrotic syndrome (NS) is caused by renal diseases that increase the permeability of the glomerular filtration barrier. It is classically characterized by four clinical features, but the first two are generally used for a clinical diagnosis.

Nephrotic range proteinuria – Urine protein excretion >50 mg/kg per day or a spot urine sample with a ratio (UP/UCr) greater than 3 mg of protein per mg creatinine (see "Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children", section on 'Urine protein excretion')

Hypoalbuminemia – Serum albumin <3 g/dL (30 g/L)

Edema

Hyperlipidemia

                                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 06 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.
  2. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98:561.
  3. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124:747.
  4. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28:415.
  5. Samuel S, Bitzan M, Zappitelli M, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am J Kidney Dis 2014; 63:354.
  6. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.
  7. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.
  8. Vivarelli M, Moscaritolo E, Tsalkidis A, et al. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J Pediatr 2010; 156:965.
  9. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2005; :CD001533.
  10. Sinha A, Saha A, Kumar M, et al. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. Kidney Int 2015; 87:217.
  11. Yoshikawa N, Nakanishi K, Sako M, et al. A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2015; 87:225.
  12. Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2015; :CD001533.
  13. Hodson EM, Hahn D, Craig JC. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2015; 30:1043.
  14. Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch Dis Child 2016; 101:404.
  15. Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr 1983; 103:553.
  16. Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004; 351:868.
  17. Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol 2006; 17:1151.
  18. MacHardy N, Miles PV, Massengill SF, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 2009; 24:2193.
  19. Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.
  20. Murnaghan K, Vasmant D, Bensman A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr Scand 1984; 73:733.
  21. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007; :CD001533.
  22. Teeninga N, Kist-van Holthe JE, van den Akker EL, et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int 2014; 85:1444.
  23. Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 1982; 101:514.
  24. Broyer M, Meyrier A, Niaudet P, Habib R. Minimal changes and focal and segmental glomerular sclerosis. In: Oxford Textbook of Clinical Nephrology, Cameron JS, Davison MA, Grünfeld JP, et al (Eds), Oxford Medical Publications, 1992. p.298.
  25. Welch TR, Gianis J, Sheldon CA. Perforation of the scrotum complicating nephrotic syndrome. J Pediatr 1988; 113:336.
  26. MacDonald NE, Wolfish N, McLaine P, et al. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 1986; 108:378.
  27. Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 2008; 93:226.
  28. Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome. Nephron 2000; 85:343.
  29. Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:63.
  30. Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1988; 113:249.
  31. Polito C, Oporto MR, Totino SF, et al. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand 1986; 75:245.
  32. FLEISHER DS, McCRORY WW, RAPOPORT M. The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. J Pediatr 1960; 57:192.
  33. Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child 2010; 95:146.
  34. Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982; 57:30.
  35. Ng JS, Wong W, Law RW, et al. Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol 2001; 29:239.
  36. Fakhouri F, Bocquet N, Taupin P, et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 2003; 41:550.
  37. Abeyagunawardena AS, Hindmarsh P, Trompeter RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch Dis Child 2007; 92:585.
  38. Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012; 27:2073.
  39. Cameron JS, Chantler C, Ogg CS, White RH. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. Br Med J 1974; 4:7.
  40. Chiu J, Drummond KN. Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome. J Pediatr 1974; 84:825.
  41. McDonald J, Murphy AV, Arneil GC. Long-term assessment of cyclophosphamide therapy for nephrosis in children. Lancet 1974; 2:980.
  42. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2013; :CD002290.
  43. Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 2003; 18:661.
  44. Azib S, Macher MA, Kwon T, et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:927.
  45. Cammas B, Harambat J, Bertholet-Thomas A, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 2011; 26:178.
  46. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 1982; 306:451.
  47. Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 2007; 49:592.
  48. Zagury A, de Oliveira AL, de Moraes CA, et al. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26:915.
  49. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62:1102.
  50. Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child 1990; 65:1147.
  51. Donia AF, Gazareen SH, Ahmed HA, et al. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant 2003; 18:2054.
  52. Trompeter RS. Immunosuppressive therapy in the nephrotic syndrome in children. Pediatr Nephrol 1989; 3:194.
  53. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16:271.
  54. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr 1978; 92:299.
  55. Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 1985; 291:1457.
  56. Müller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. A case report and review of the literature. Eur J Pediatr 1981; 136:105.
  57. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978; 93:516.
  58. Mongeau JG, Robitaille PO, Roy F. Clinical efficacy of levamisole in the treatment of primary nephrosis in children. Pediatr Nephrol 1988; 2:398.
  59. Alsaran K, Grisaru S, Stephens D, Arbus G. Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2001; 56:289.
  60. Barletta GM, Smoyer WE, Bunchman TE, et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol 2003; 18:833.
  61. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991; 337:1555.
  62. Boyer O, Moulder JK, Grandin L, Somers MJ. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 2008; 23:575.
  63. Sümegi V, Haszon I, Iványi B, et al. Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol 2004; 19:1354.
  64. Elmas AT, Tabel Y, Elmas ON. Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome. Int Urol Nephrol 2013; 45:1047.
  65. Davin JC, Merkus MP. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol 2005; 20:10.
  66. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994; 5:1049.
  67. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 1991; 35 Suppl 1:S31.
  68. Tejani AT, Butt K, Trachtman H, et al. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988; 33:729.
  69. Kano K, Kyo K, Yamada Y, et al. Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 1999; 52:19.
  70. Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20:735.
  71. Habib R, Niaudet P. Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42:141.
  72. Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 2008; 73:1167.
  73. Kengne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4:1409.
  74. Ishikura K, Yoshikawa N, Nakazato H, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol 2012; 7:1576.
  75. Ishikura K, Yoshikawa N, Nakazato H, et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol 2015; 30:459.
  76. Dötsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 2006; 21:1761.
  77. Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006; 21:1848.
  78. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42:1114.
  79. Novak I, Frank R, Vento S, et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20:1265.
  80. Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1:1173.
  81. Fujinaga S, Ohtomo Y, Umino D, et al. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:71.
  82. Afzal K, Bagga A, Menon S, et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007; 22:2059.
  83. Banerjee S, Pahari A, Sengupta J, Patnaik SK. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 2013; 28:93.
  84. Dehoux L, Hogan J, Dossier C, et al. Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol 2016; 31:2095.
  85. Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008; 146A:1.
  86. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008; 23:2013.
  87. Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013; 24:1689.
  88. Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269.
  89. Fujinaga S, Hirano D, Nishizaki N, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010; 25:539.
  90. Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2010; 25:1109.
  91. Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1308.
  92. Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013; 84:1025.
  93. Iijama K, Sako M, Nozu K, et al. Rituximab for childhood-onset,complciated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014.
  94. Sinha A, Bhatia D, Gulati A, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 2015; 30:96.
  95. Webb H, Jaureguiberry G, Dufek S, et al. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol 2016; 31:589.
  96. Ravani P, Rossi R, Bonanni A, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol 2015; 26:2259.
  97. Kamei K, Ogura M, Sato M, et al. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol 2016; 31:89.
  98. Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009; 24:1321.
  99. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433.
  100. Boyer O, Niaudet P. Nephrotic syndrome: Rituximab in childhood steroid-dependent nephrotic syndrome. Nat Rev Nephrol 2013; 9:562.
  101. Hodson EM, Craig JC. Rituximab for childhood-onset nephrotic syndrome. Lancet 2014.
  102. Sellier-Leclerc AL, Belli E, Guérin V, et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013; 28:1875.
  103. Kamei K, Takahashi M, Fuyama M, et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 2015; 30:91.
  104. Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol 2012; 23:975.
  105. Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753.
  106. Ahn YH, Kang HG, Lee JM, et al. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol 2014; 29:1461.
  107. Straatmann C, Ayoob R, Gbadegesin R, et al. Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatr Nephrol 2013; 28:1235.
  108. Srivastava RN, Agarwal RK, Moudgil A, Bhuyan UN. Late resistance to corticosteroids in nephrotic syndrome. J Pediatr 1986; 108:66.
  109. Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68:1275.
  110. Rüth EM, Kemper MJ, Leumann EP, et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 2005; 147:202.
  111. Kyrieleis HA, Löwik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4:1593.